retatrutide obesity clinical trial results ⭐️topline from TRIUMPH-1, a Phase 3 evaluating #retatrutide, an investigational GIP / GLP-1 / glucagon triple hormone receptor agonist, in adults with or “overweight” retatrutide side effects clinical trial

BPC-157, short for Body Protective Compound 157, is a peptide originally derived from a protein found in the stomach

Dysmenorrhea is a condition characterized by severe and frequent menstrual pain, such as cramps and pelvic pain

Email: [email protected]

MedicalDaily Evidence Check Study type: Cross-sectional observational study using self-reported survey data Institution: Rutgers University (New Jersey Gun Violence Research Center, School of Public Health) Published in: Criminology, June 17, 2026 Participants: 821 GLP-1 users within a nationally representative survey of 7,521 adults What it found: The impulsivity-violence link was approximately 62% weaker among current GLP-1 users vs